Login to Your Account

NewCo News: Stealth Moves Mitochondrial Candidate into Phase II Trials

By Marie Powers

Friday, October 7, 2011
Despite its moniker, privately held Stealth Peptides Inc. is poised to make a name for itself in the development of mitochondrial-targeted therapies, potentially addressing cardiovascular, renal, ophthalmologic, neurologic and metabolic indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription